{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T09:25:00Z","timestamp":1766136300031},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,3,20]],"date-time":"2012-03-20T00:00:00Z","timestamp":1332201600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Fam Pract"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1471-2296-13-23","type":"journal-article","created":{"date-parts":[[2012,3,21]],"date-time":"2012-03-21T22:58:22Z","timestamp":1332370702000},"source":"Crossref","is-referenced-by-count":22,"title":["Non-steroidal anti-inflammatory drugs for the treatment of pain and immobility-associated osteoarthritis: consensus guidance for primary care"],"prefix":"10.1186","volume":"13","author":[{"given":"Ade","family":"Adebajo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,3,20]]},"reference":[{"key":"682_CR1","volume-title":"Annual prevalence report","author":"Royal College of General Practioners - Birmingham Research Unit","year":"2006","unstructured":"Royal College of General Practioners - Birmingham Research Unit: Annual prevalence report. 2006, Accessed at \n                    http:\/\/www.rcgp.org.uk\/pdf\/Annual%20prevalence%20report%202006.pdf\n                    \n                   on January 25, 2012"},{"key":"682_CR2","doi-asserted-by":"publisher","first-page":"d1165","DOI":"10.1136\/bmj.d1165","volume":"342","author":"E Nuesch","year":"2011","unstructured":"Nuesch E, Dieppe P, Reichenbach S, Williams S, Iff S, Juni P: All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. BMJ. 2011, 342: d1165-10.1136\/bmj.d1165.","journal-title":"BMJ"},{"key":"682_CR3","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1177\/147323000102900602","volume":"29","author":"AJ Kivitz","year":"2001","unstructured":"Kivitz AJ, Moskowitz RW, Woods E, Hubbard RC, Verburg KM, Lefkowith JB, Geis GS: Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip. J Int Med Res. 2001, 29: 467-479.","journal-title":"J Int Med Res"},{"key":"682_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/030097401750065265","volume":"30","author":"F McKenna","year":"2001","unstructured":"McKenna F, Borenstein D, Wendt H, Wallemark C, Lefkowith JB, Geis GS: Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol. 2001, 30: 11-18. 10.1080\/030097401750065265.","journal-title":"Scand J Rheumatol"},{"key":"682_CR5","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1592\/phco.19.16.1269.30879","volume":"19","author":"SZ Zhao","year":"1999","unstructured":"Zhao SZ, McMillen JI, Markenson JA, Dedhiya SD, Zhao WW, Osterhaus JT, Yu SS: Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib. Pharmacotherapy. 1999, 19: 1269-1278. 10.1592\/phco.19.16.1269.30879.","journal-title":"Pharmacotherapy"},{"key":"682_CR6","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1365-2036.2008.03905.x","volume":"29","author":"A Rostom","year":"2009","unstructured":"Rostom A, Moayyedi P, Hunt R: Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther. 2009, 29: 481-496. 10.1111\/j.1365-2036.2008.03905.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"682_CR7","volume-title":"Osteoarthritis: The care and management of osteoarthritis in adults NICE clinical guideline 59","author":"National Institute for Health and Clinical Excellence (NICE)","year":"2008","unstructured":"National Institute for Health and Clinical Excellence (NICE): Osteoarthritis: The care and management of osteoarthritis in adults NICE clinical guideline 59. 2008"},{"key":"682_CR8","doi-asserted-by":"publisher","first-page":"c7086","DOI":"10.1136\/bmj.c7086","volume":"342","author":"S Trelle","year":"2011","unstructured":"Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, Egger M, Juni P: Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011, 342: c7086-10.1136\/bmj.c7086.","journal-title":"BMJ"},{"key":"682_CR9","volume-title":"EMEA\/97949\/2004 London","author":"European Medicines Agency","year":"2004","unstructured":"European Medicines Agency: EMEA statement following withdrawal of Vioxx (rofecoxib). EMEA\/97949\/2004 London. 2004"},{"key":"682_CR10","volume-title":"EMEA\/358324\/2005 London","author":"European Medicines Evaluation Agency","year":"2005","unstructured":"European Medicines Evaluation Agency: EMEA Public statement on the suspension of the marketing authorisation for Bextra (valdecoxib) in the European Union. EMEA\/358324\/2005 London. 2005"},{"key":"682_CR11","volume-title":"EMEA\/CHMP\/579301\/2007 London","author":"European Medicines Agency","year":"2007","unstructured":"European Medicines Agency: European Medicines Agency recommends withdrawal of the marketing authorisations for lumiracoxib containing medicines. EMEA\/CHMP\/579301\/2007 London. 2007"},{"key":"682_CR12","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1177\/002188637100700404","volume":"VII","author":"AL Delbecq","year":"1971","unstructured":"Delbecq AL, Vandeven AH: A group process model for problem identification and program planning. J Appl Behav Sci. 1971, VII: 466-491.","journal-title":"J Appl Behav Sci"},{"key":"682_CR13","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1161\/01.CIR.83.1.356","volume":"83","author":"KM Anderson","year":"1991","unstructured":"Anderson KM, Wilson PW, Odell PM, Kannel WB: An updated coronary risk profile. A statement for health professionals. Circulation. 1991, 83: 356-362.","journal-title":"Circulation"},{"issue":"Suppl 5","key":"682_CR14","first-page":"v1","volume":"91","author":"Joint British Societies","year":"2005","unstructured":"Joint British Societies: JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005, 91 (Suppl 5): v1-52.","journal-title":"Heart"},{"key":"682_CR15","volume-title":"Nonsteroidal anti-inflammatory drugs (standard or coxibs) - prescribing issues - Management. Who is at increased risk of gastrointestinal adverse effects from oral NSAIDs?","author":"NHS Clinical Knowledge Service","year":"2008","unstructured":"NHS Clinical Knowledge Service: Nonsteroidal anti-inflammatory drugs (standard or coxibs) - prescribing issues - Management. Who is at increased risk of gastrointestinal adverse effects from oral NSAIDs?. 2008, Accessed at \n                    http:\/\/www.cks.nhs.uk\/nsaids_prescribing_issues\/management\/detailed_answers\/gastrointestinal_adverse_effects\/people_at_increased_risk\n                    \n                   on January 25, 2012"},{"key":"682_CR16","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1001\/jama.296.13.jrv60011","volume":"296","author":"P McGettigan","year":"2006","unstructured":"McGettigan P, Henry D: Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006, 296: 1633-1644. 10.1001\/jama.296.13.jrv60011.","journal-title":"JAMA"},{"key":"682_CR17","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1136\/bmj.312.7046.1563","volume":"312","author":"D Henry","year":"1996","unstructured":"Henry D, Lim LL, Garcia Rodriguez LA, Perez Gutthann S, Carson JL, Griffin M, Savage R, Logan R, Moride Y, Hawkey C, et al: Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ. 1996, 312: 1563-1566. 10.1136\/bmj.312.7046.1563.","journal-title":"BMJ"},{"key":"682_CR18","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.amjcard.2007.11.054","volume":"101","author":"PA Gladding","year":"2008","unstructured":"Gladding PA, Webster MW, Farrell HB, Zeng IS, Park R, Ruijne N: The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol. 2008, 101: 1060-1063. 10.1016\/j.amjcard.2007.11.054.","journal-title":"Am J Cardiol"},{"key":"682_CR19","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/AJP.0b013e31816b2f26","volume":"24","author":"JC Ballantyne","year":"2008","unstructured":"Ballantyne JC, Shin NS: Efficacy of opioids for chronic pain: a review of the evidence. Clin J Pain. 2008, 24: 469-478. 10.1097\/AJP.0b013e31816b2f26.","journal-title":"Clin J Pain"},{"key":"682_CR20","doi-asserted-by":"publisher","first-page":"c3533","DOI":"10.1136\/bmj.c3533","volume":"341","author":"KM Dunn","year":"2010","unstructured":"Dunn KM, Hay EM: Opioids for chronic musculoskeletal pain. BMJ. 2010, 341: c3533-10.1136\/bmj.c3533.","journal-title":"BMJ"},{"key":"682_CR21","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1001\/archinternmed.2010.391","volume":"170","author":"DH Solomon","year":"2010","unstructured":"Solomon DH, Rassen JA, Glynn RJ, Lee J, Levin R, Schneeweiss S: The comparative safety of analgesics in older adults with arthritis. Arch Intern Med. 2010, 170: 1968-1976. 10.1001\/archinternmed.2010.391.","journal-title":"Arch Intern Med"},{"key":"682_CR22","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1136\/bmj.330.7504.1366","volume":"330","author":"J Hippisley-Cox","year":"2005","unstructured":"Hippisley-Cox J, Coupland C: Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. 2005, 330: 1366-10.1136\/bmj.330.7504.1366.","journal-title":"BMJ"},{"key":"682_CR23","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1001\/archinternmed.2008.525","volume":"169","author":"GH Gislason","year":"2009","unstructured":"Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Fosbol EL, Sorensen R, Folke F, Buch P, Gadsboll N, et al: Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med. 2009, 169: 141-149. 10.1001\/archinternmed.2008.525.","journal-title":"Arch Intern Med"},{"key":"682_CR24","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1161\/CIRCULATIONAHA.110.004671","volume":"123","author":"AM Schjerning Olsen","year":"2011","unstructured":"Schjerning Olsen AM, Fosbol EL, Lindhardsen J, Folke F, Charlot M, Selmer C, Lamberts M, Bjerring Olesen J, Kober L, Hansen PR, et al: Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation. 2011, 123: 2226-2235. 10.1161\/CIRCULATIONAHA.110.004671.","journal-title":"Circulation"},{"key":"682_CR25","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1056\/NEJM200009213431202","volume":"343","author":"A Lanas","year":"2000","unstructured":"Lanas A, Bajador E, Serrano P, Fuentes J, Carreno S, Guardia J, Sanz M, Montoro M, Sainz R: Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. New Engl J Med. 2000, 343: 834-839. 10.1056\/NEJM200009213431202.","journal-title":"New Engl J Med"},{"key":"682_CR26","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa021907","volume":"347","author":"FK Chan","year":"2002","unstructured":"Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, Hui AJ, To KF, Leung WK, Wong VW, et al: Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. New Engl J Med. 2002, 347: 2104-2110. 10.1056\/NEJMoa021907.","journal-title":"New Engl J Med"},{"key":"682_CR27","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.amjmed.2005.04.031","volume":"118","author":"KC Lai","year":"2005","unstructured":"Lai KC, Chu KM, Hui WM, Wong BC, Hu WH, Wong WM, Chan AO, Wong J, Lam SK: Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med. 2005, 118: 1271-1278. 10.1016\/j.amjmed.2005.04.031.","journal-title":"Am J Med"},{"key":"682_CR28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0140-6736(10)60673-3","volume":"376","author":"FK Chan","year":"2010","unstructured":"Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL: Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010, 376: 173-179. 10.1016\/S0140-6736(10)60673-3.","journal-title":"Lancet"},{"key":"682_CR29","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.ahj.2008.12.014","volume":"157","author":"MC Becker","year":"2009","unstructured":"Becker MC, Wang TH, Wisniewski L, Wolski K, Libby P, Luscher TF, Borer JS, Mascette AM, Husni ME, Solomon DH, et al: Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. Am Heart J. 2009, 157: 606-612. 10.1016\/j.ahj.2008.12.014.","journal-title":"Am Heart J"},{"key":"682_CR30","volume-title":"Clinicaltrials.gov [internet]. National Library of Medicine (US). 2006- [cited June 2 2011] NLM Identifier NCT00346216","author":"Pfizer and The Cleveland Clinic","year":"2006","unstructured":"Pfizer and The Cleveland Clinic: Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen (PRECISION). Clinicaltrials.gov [internet]. National Library of Medicine (US). 2006- [cited June 2 2011] NLM Identifier NCT00346216. 2006, Available from: \n                    http:\/\/www.clinicaltrials.gov\/ct2\/show\/study\/NCT00346216?term=PRECISION+celecoxib&rank=1\n                    \n                   accessed on January 25, 2012, - [cited June 2 2011] NLM Identifier NCT00346216"},{"key":"682_CR31","first-page":"11","volume":"49","author":"C Watkins","year":"1999","unstructured":"Watkins C, Harvey I, Langley C, Gray S, Faulkner A: General practitioners' use of guidelines in the consultation and their attitudes to them. Br J Gen Pract. 1999, 49: 11-15.","journal-title":"Br J Gen Pract"},{"key":"682_CR32","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1136\/bmj.318.7182.527","volume":"318","author":"SH Woolf","year":"1999","unstructured":"Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J: Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines. BMJ. 1999, 318: 527-530. 10.1136\/bmj.318.7182.527.","journal-title":"BMJ"},{"key":"682_CR33","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.clinthera.2010.04.009","volume":"32","author":"JM Scheiman","year":"2010","unstructured":"Scheiman JM, Hindley CE: Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin Ther. 2010, 32: 667-677. 10.1016\/j.clinthera.2010.04.009.","journal-title":"Clin Ther"},{"key":"682_CR34","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1161\/CIRCULATIONAHA.106.181424","volume":"115","author":"EM Antman","year":"2007","unstructured":"Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA: Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007, 115: 1634-1642. 10.1161\/CIRCULATIONAHA.106.181424.","journal-title":"Circulation"}],"container-title":["BMC Family Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2296-13-23\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2296-13-23.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2296-13-23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2296-13-23.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T16:10:37Z","timestamp":1548259837000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcfampract.biomedcentral.com\/articles\/10.1186\/1471-2296-13-23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,20]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["682"],"URL":"https:\/\/doi.org\/10.1186\/1471-2296-13-23","relation":{},"ISSN":["1471-2296"],"issn-type":[{"value":"1471-2296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,20]]},"article-number":"23"}}